As most patients with triple-negative breast cancer (TNBC) (60–80%) exhibit mutations in BRCA1 and AR activity is directly influenced by BRCA1, AR can potentially be a prognostic marker for TNBC14. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.